Event Participants
Executives
3 Neelesh Garg (Chairman & MD), Prashant Madhur (CEO), Rishabh Mehta (Interim CFO)
Analysts
7 Mahesh Kumar (MU Investments), Manaswini Mukherjee (Oracle), Maria Mittal (Individual Investor), Nimish Pandya (NP Investments), Pariksha Jain (Motilal Oswal), Prakhar Porwal (Ambit Capital), Yogesh (NYN Associates)
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Production | 408 MW | -40% YoY (685 MW Q1 FY26); -56% QoQ (935 MW Q4 FY26). Lower execution volumes from customer-led delays and selective order intake to preserve margins |
| Sales Volume | 334 MW | -42% YoY (579 MW Q1 FY26); -68% QoQ (1,050 MW Q4 FY26). Retail sales excluded from order book, traditionally ~20% of monthly sales |
| Revenue from Operations | ₹511 crore | -44% YoY (₹916 crore Q1 FY26); -68% QoQ (₹1,608 crore Q4 FY26). Volume-led decline amid geopolitical disruptions (Iran war), commodity volatility and elevated logistics costs |
| EBITDA | ₹42.5 crore | Margin 8.33% vs 7.25% Q4 FY26 (+108 bps QoQ); vs ₹177.7 crore in Q1 FY26. Margin resilience aided by disciplined procurement and selective execution |
| Profit After Tax | ₹5.4 crore | -95% YoY (₹116.6 crore Q1 FY26); -91% QoQ (₹60.4 crore Q4 FY26). Operating deleverage from low volumes outweighed margin improvement |
| Order Book | ~6.35 GW | ≈ ₹8,200 crore; 132% of 4.8 GW module capacity. 30% DCR domestic-cell orders, 70% utility / 30% C&I mix; 30-40% of utility orders are variable-price |
| Debt-to-Equity | 0.99 | Debt at ~₹1,250 crore, primarily funding Odisha plant. Peak net debt of ₹2,200-2,400 crore expected as Phase 2 capex progresses |
Geographic & Segment Commentary
Module Manufacturing (India): Core segment; Q1 FY27 production of 408 MW and sales of 334 MW. Margins compressed to 8.33% as wait-and-watch customer behavior (ALM1→ALM2 transition), commodity price spikes, freight costs and FX volatility persisted. Management prioritized contribution over volume, executing only commercially attractive orders.
Cell Manufacturing (Odisha, Phase 1): 2.4 GW cell + 4 GW module facility across 57 acres approaching operational readiness. Equipment installation near complete; ALM2 inspection planned for September 2026. Ramp-up targeted at ~200 MW/month (full 2.4 GW in ~3 months), with ~80% utilization expected by Q4 FY27.
Transformer & Power Electronics (Malcon): Acquired mid-Q1 FY27; in learning phase with expansion planning underway. Addressable transformer market ~₹30,000 crore, projected to grow to ~₹55,000 crore by 2031. Management targets 8-10% market share and ~₹1,500 crore transformer revenue within 3-4 years.
B2C / Distributed Solar: Entered B2C segment with Connect Solar Kit and UBE Plus Hybrid Inverter. Distribution network strengthening; retail sales (~20% of monthly volumes) executed on a rolling basis outside the tracked order book.
Company-Specific & Strategic Commentary
Integrated Manufacturing Platform: Phase 1 (2.4 GW cell + 4 GW module) on track for Q2-Q3 FY27 ramp; Phase 2 (3.6 GW cell, ~₹1,600-1,700 crore) site works starting Q2 FY27, completion by end FY28 (total cell capacity 6 GW); Phase 3 (6 GW ingot/wafer) targeted FY29, aligned with ALMC transition. Phase 1 capex ~₹1,850 crore, cumulative spend ~₹1,000 crore to date.
Backward Integration & Margin Levers: Encapsulant capacity expanding from 2 GW to 5 GW for supply-chain control; cell manufacturing expected to lift EBITDA into high-double digits once ramped. Supply chain diversified with cell sourcing from non-China FTA countries to mitigate geopolitical risk.
Momentum in Order Inflows: July 2026 — ₹138 crore domestic module order (execution by December 2026); August 11, 2026 — ~₹400 crore module orders via subsidiary (execution by March 2027), reinforcing healthy underlying demand.
Non-Module Revenue Ambition: Non-module business currently 4-5% of revenue; target ~10% in FY27 and 15% by FY28, driven by transformers (Malcon), inverters, solar kits and storage.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| FY27 Sales Volume | 3.5-4 GW | Reaffirmed despite soft Q1; supported by 6.35 GW order book, H2 cell ramp and recovery in customer procurement |
| FY27 Revenue | ~₹6,000 crore | Requires ~₹1,800 crore quarterly average in H2-FY27, implying sharp acceleration vs Q1's ₹511 crore |
| FY27 EBITDA Margin | ~12% | Driven by cell production margins (high double-digit EBITDA) and stabilizing commodity/FX environment |
| FY27 PAT Margin | 6-7% | Dependent on achieving volume targets and cell ramp; deleverage risk if Q2 volumes recover slowly |
| Cell Ramp-Up | ALM2 inspection September 2026; 80% utilization by Q4 FY27 | Ramp-up starting end-August/early-September; full 2.4 GW run-rate in ~3 months |
| Phase 2 Cell (3.6 GW) | Site work Q2 FY27; completion end FY28 | Capex ₹1,600-1,700 crore; full integration with Phase 1 infrastructure |
| Phase 3 (6 GW Ingot/Wafer) | Completion FY29 | Aligned with anticipated ALMC (non-ALMM) transition; planning initiated |
| FY28 Outlook | "Milestone year" | DCR demand to broaden to utility segment from April 2027 onward as 18-24-month utility project cycles mature; visibility provided only in Q3 FY27 call |
Risks & Constraints
| Risk | Context |
|---|---|
| Geopolitical Disruption (Iran War) | Commodity prices volatile, logistics/freight elevated, FX (INR/USD) volatility impacting imported input costs. Management hedging via multi-country cell sourcing and selective order execution; no structural protection until cell manufacturing scales. |
| ALM1→ALM2 Policy Transition | Mandatory domestic cell usage postponed from July 1, 2026 to January 1, 2027 due to domestic cell shortage. Caused customer wait-and-see behavior in Q1, deferring orders; a second postponement would again compress module-only demand. |
| Cell & Polysilicon Price Inflation | US policy changes in the two weeks prior to the call pushed cell/polysilicon prices higher. Without backward integration until H2, margin pressure evident in pure module business. |
| Ramp-Up Execution Risk | Cell line ramp-up begins end-Aug/early-Sept with ~3-month stabilization; any delay in achieving 80% utilization by Q4 FY27 would defer margin accretion and net-debt reduction. |
| Competitive Intensity in Module Segment | Crowded module-only market is structurally margin-dilutive; management explicitly avoided volume-at-any-cost orders. Sustained competition until integrated supply is online could keep module margins near current levels. |
Q&A Highlights
Margin Protection & Compression Drivers
- Question: What specific initiatives protect margins, and why did Q1 margins compress despite a strong order book? (Yogesh/NYN; Mahesh Kumar/MU Investments)
- Answer: Three levers: (1) accelerating cell manufacturing with ALM2 inspection in September and production in Q3 FY27, expected to lift EBITDA into high double digits; (2) expanding encapsulant capacity from 2 GW to 5 GW; (3) diversifying cell procurement beyond China to FTA countries. Compression in Q1 stemmed from the Iran war (commodity, freight, FX), customer wait-and-watch on ALM2 timing, and selective order execution when input costs exceeded transferable prices. Management noted module EBITDA was 7.25% in Q4 FY26 vs 8.33% now — margin actually improved QoQ. (Neelesh Garg)
Cell Ramp-Up & Utilization Timeline
- Question: When will the cell facility reach commercial production and what utilization is expected in FY27? (Manaswini Mukherjee/Oracle)
- Answer: Equipment installation in progress at Odisha; ramp-up begins end-August/early-September 2026. ALM2 inspection in September. First phase = 2.4 GW (≈200 MW/month); full ramp in ~3 months → ~80% utilization by Q4 FY27. (Neelesh Garg)
Margin Trajectory with Integration
- Question: How should we model EBITDA margins as the integrated platform scales? (Mahesh Kumar/MU Investments)
- Answer: With ALM2's domestic-cell mandate postponed to January 1, 2027, DCR (domestic cell) modules command pricing power. Planned margin on DCR cell sales is 18-20%. Cell production is expected to drive significant EBITDA uplift to high-double-digit levels — no precise number provided. Volume recovery expected from Q2, but near-term margins remain hostage to geopolitical factors and recent US-driven cell/polysilicon price increases. (Neelesh Garg)
Order Book Composition & Pricing Structure
- Question: What is the mix of contracts (fixed vs pass-through) and how execrable is the current book? (Prakhar Porwal/Ambit)
- Answer: 6.35 GW ≈ ₹8,200 crore. Segment-wise:
70% utility, ~30% C&I. Pricing: ~100% of C&I orders are fixed-price; utility segment split ~30-40% variable-price (commodity pass-through), rest fixed. DCR orders (30% of book) are being secured for in-house cell production from Q3 onward — currently cells are procured externally for DCR spot orders. Execution horizon 12-18 months. (Neelesh Garg)
Capital Structure, Debt Peak & Capex Plan
- Question: Where does debt peak and what is the FY27/FY28 capex envelope? (Prakhar Porwal/Ambit)
- Answer: Current total debt ~₹1,250 crore (incurred capex ~₹1,000 crore). Phase 1 (2.4 GW cell + 4 GW module) total capex ~₹1,850 crore; Phase 2 (3.6 GW cell) ~₹1,600-1,700 crore; cumulative ~₹3,500 crore. Expected peak net debt of ₹2,200-2,400 crore, with internal accruals funding the balance. Phase 2 completion targeted end-FY28. (Rishabh Mehta, Neelesh Garg)
ALM2 Transition & Demand Environment
- Question: Why did Q1 miss the expected ALM2-driven volume bump, and how does demand shape up? (Prakhar Porwal/Ambit)
- Answer: War-induced input-cost inflation made projects unviable; force majeure notices and tariff differentials (pre-June 30 vs post-July 31 commissioning) created uncertainty. Developers deferred in May-June awaiting policy clarity on DCR extension. Management clarified this was demand-side deferral, not loss of demand — orders received in July/August (₹138 crore + ~₹400 crore) validate the recovery trajectory. (Neelesh Garg)
FY27 Guidance & FY28 Outlook
- Question: Can you confirm FY27 guidance and provide FY28 color? (Maria Mittal/Individual Investor; Pariksha Jain/Motilal Oswal)
- Answer: FY27 reaffirmed: 3.5-4 GW sales, ~₹6,000 crore revenue, ~12% EBITDA margin, 6-7% PAT margin. FY28 commentary deferred to Q3 FY27 call — management flagged FY28 as a "milestone year" because large utility DCR project demand (18-24-month cycle) matures only from April 2027 onward, on top of existing retail/C&I/Kusum demand. Upward bias to guidance if geopolitical conditions normalize. (Neelesh Garg)
Business Diversification & Transformer Ambition
- Question: Which segments (EPC, IPP, storage, B2C, transformers) become meaningful EBITDA contributors? (Maria Mittal/Individual Investor; Nimish Pandya/NP Investments)
- Answer: Non-module business targeted at ~15% of revenue by FY28 (from 4-5% today). Transformer business (Malcon): ₹30,000 crore market slated to reach ₹55,000 crore by 2031; company targets 8-10% share, building toward ~₹1,500 crore transformer revenue in 3-4 years. Vision: increase value capture from ~25% of project cost (module) to 40-50% via cells, transformers, inverters and storage. (Neelesh Garg)
Order Book Value, DCR Margins & Execution Timeline
- Question: What is the INR value of the order book, and what margins do DCR orders carry? (Pariksha Jain/Motilal Oswal; retail investor)
- Answer: Order book ≈ ₹8,200 crore. DCR orders in the book assume in-house cell production with ~18-20% margins on the cell component (external-cell spot orders excluded from the book). Order execution horizon 12-18 months excluding rolling retail volumes. (Neelesh Garg)
Key Takeaway
Saatvik Green Energy delivered a deliberately conservative Q1 FY27 — production fell 40% YoY to 408 MW, revenue dropped 44% YoY to ₹511 crore, and PAT collapsed 95% YoY to ₹5.4 crore — as management chose margin discipline over volume amid Iran-war-driven commodity spikes, freight inflation, FX volatility and customer-side ALM2 transition delays. EBITDA margin nonetheless improved to 8.33% (+108 bps QoQ), reflecting selective order execution and diversified cell sourcing. The 6.35 GW order book (₹8,200 crore; 132% module-capacity coverage) and fresh July-August wins (~₹538 crore) underpin management's reaffirmed FY27 guidance of 3.5-4 GW sales, ~₹6,000 crore revenue and ~12% EBITDA margin. The pivotal driver is the Odisha cell line: ALM2 inspection is slated for September 2026, with ~80% utilization targeted by Q4 FY27 and DCR cell margins of 18-20%, which management expects to push EBITDA into high double digits. Phase 2 (3.6 GW cell, FY28) and Phase 3 (6 GW ingot/wafer, FY29) extend the integration roadmap. Peak net debt of ₹2,200-2,400 crore, cell/polysilicon price inflation and geopolitical volatility remain the key watchpoints; management positions FY28 as a "milestone year" as utility-scale DCR demand matures, with further guidance deferred to the Q3 FY27 call.